Funds for the development of its anti-Tau drug against neurodegenerative diseases
Bernville, Pa., October 18, 2022 /CNW/ – Treventis Corporation, a private biotechnology company, today announced that its proposal for the preclinical development of a small molecule anti-tau drug has received funding totaling $2,977,166 by the Congressional Directed Medical Research Programs (CDMRP), which is part of the DOD.
Treventis’ proposal, “Development of a Small Molecule Anti-Folding Drug for Frontotemporal Degeneration”, was submitted in response to the FY21 Peer-Reviewed Medical Research Program – Technology Development Award /therapeutic (PRMRP-TTDA), which was solicited for the Defense Health Agency (DHA) J9, Research and Development Directorate, by the US Army Medical Research Acquisition Activity (USAMRAA).
Frontotemporal degeneration (FTD) is a major cause of dementia, which in many patients is triggered by an aberrant release of tau protein that would otherwise be bound to microtubules. This overabundance of free tau allows the formation of pathogenic oligomers that can lead to synapto and neurotoxicity in FTD. The award aims to complete the manufacture of an anti-tau small molecule of Treventis in a manner consistent with Good Manufacturing Practices (GMP) and to collect additional efficacy, pharmacology and safety data in accordance with Good Manufacturing Practices (GMP). Laboratory Practices (GLP) in ultimate support of a Research New Drug Application (IND) with the Food and Drug Administration (FDA). This work will be undertaken by Treventis and a network of selected contract research organizations overseen by Treventis.
“We are delighted and pleased with the funding from the DoD and the feedback from their scientific review. Treventis believes that a small molecule targeting tau has significant potential as a therapeutic for diseases related to protein misfolding such as FTD,” said Dr. Christopher Bardon, CEO of Treventis. Dr. Donald Weaver, Principal Investigator on the study and Chief Medical Officer of Treventis, added: “This funding will allow Treventis to introduce important new hypotheses about targeting protein misfolding disease in a new stage of validation, bringing a small molecule anti-tau that much closer to making a difference in the lives of dementia patients and their caregivers. »
TREVENTIS™ Corporation is dedicated to the treatment and prevention of diseases related to protein misfolding. We use a proprietary patent-pending discovery engine – Common Conformational Morphology (CCM) – to identify drug active sites in misfolded protein targets. CCM combines silicone models with deep expertise in model development (in vitro, ex vivo, in vivo) to enable rational drug design against misfolded protein targets. Our core program focuses on protection against bend errorssoft mallecules in tauopathy (3R, 4R, familial and mixed mutations) with relevance to Alzheimer’s disease and frontotemporal degeneration. We have other efforts in oncology and other neurodegenerative diseases (ALS, Parkinson’s) that show the great utility of our technology platform for the design and development of small molecules in protein misfolding disease. More information on www.treventis.com
About the PRMRP
The Peer-Reviewed Medical Research Program (PRMRP), established in fiscal year 1999 (FY99), supported research across the full spectrum of science and medicine, with the underlying goal of improving the health, care and welfare of military service members. , veterans, retirees and their family members. Throughout history, military medical research has pioneered reconstructive surgery, the use of antibiotics, intensive care, burn care, and kidney dialysis in response to wartime needs, to the benefit soldiers and civilians. The medical research supported by the PRMRP to meet short-term military needs, including military and personal preparedness, continues this tradition. The PRMRP is committed to supporting research that has the potential to have a profound impact on the development and implementation of medical devices, medicines and clinical guidance that will improve the accuracy and effectiveness of prevention, diagnosis and treatment in a wide range of disciplines. For more information visit cdmrp.health.mil/prmrp/
This work will be supported by the Office of the Assistant Secretary of Defense for Health Affairs and the Defense Health Agency J9, Research and Development Directorate, or the US Army Medical Research Acquisition Activity at the US Army Medical Research and Development Command, for a amount of $2,977,166, through the PRMRP-TTDA under decision number W81XWH-22-1-0746. The opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Department of Defense.
View original content: https://www.prnewswire.com/news-releases/treventis-awarded-2-97m-grant-from-the-us-department-of-defense-301651229.html
SOURCE TREVENTIS Corporation